Long-Term Performance of the COMBO Dual-Therapy Stent: Results from the REMEDEE Registry.
Cardiovasc Revasc Med
; 21(5): 567-570, 2020 05.
Article
en En
| MEDLINE
| ID: mdl-31662276
ABSTRACT
BACKGROUND:
Data of long-term safety and efficacy of the COMBO dual-therapy stent is lacking. REMEDEE Registry evaluated the COMBO stent and showed low clinical event rates up to 3â¯year. We report the clinical outcomes at 4-year follow-up of this registry.METHODS:
The REMEDEE Registry is a prospective, multicenter registry with minimal exclusion criteria, evaluating clinical outcomes after treatment with the COMBO stent. A 1000 patients were enrolled between June 2013 and March 2014. Target lesion failure (TLF), defined as a composite of cardiac death, target-vessel myocardial infarction (TV-MI) and target lesion revascularization (TLR), at 4-year follow-up was the primary focus of this analysis.RESULTS:
Four-year follow-up data were obtained in 97.3% of patients. TLF was present in 117 patients (11.9%). Cardiac death occurred in 45 patients (4.6%), TV-MI was observed in 25 patients (2.6%) and TLR was performed in 73 patients (7.5%). Of the 7.5% TLR at 4â¯years, 1.5% were beyond 2â¯years. Definite ST was seen in 7 patients (0.7%) and probable ST in 1 (0.1%). No definite or probable ST occurred between 3 and 4â¯years follow-up. At 4-year follow-up, 93.1% of patients were free of ischemic symptoms.CONCLUSION:
This registry showed excellent 4-year results after COMBO stent placement, with no ST beyond 3â¯years.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Enfermedad de la Arteria Coronaria
/
Síndrome Coronario Agudo
/
Stents Liberadores de Fármacos
/
Intervención Coronaria Percutánea
Tipo de estudio:
Clinical_trials
/
Etiology_studies
/
Observational_studies
/
Risk_factors_studies
País/Región como asunto:
Europa
Idioma:
En
Revista:
Cardiovasc Revasc Med
Asunto de la revista:
ANGIOLOGIA
/
CARDIOLOGIA
Año:
2020
Tipo del documento:
Article